Shanghai ST-segment Elevation Myocardial Infarction Cohort

A Prospective Multicentre Cohort Study of Acute ST-segment Elevation Myocardial Infarction

ST-segment elevation myocardial infarction(STEMI) remains a major cause of morbidity and mortality worldwide, despite of the early reperfusion therapy, including fibrinolysis, primary percutaneous coronary intervention (PCI),and standardized medical treatment.To improve the prognosis of STEMI patients, the management in their hospitalization should be optimized, including improvements in risk stratification, more widespread use of an invasive strategy, implementation of care delivery systems prioritising immediate revascularisation through PCI (or fibrinolysis), advances in antiplatelet agents and anticoagulants, and greater use of secondary prevention strategies such as lipid-lowering therapy.

This study aims to standardized the management of STEMI patients and improve the prognosis of the STEMI patients.

This study is a prospective cohort study. It aims to standardized the management of STEMI patients and improve the prognosis of the STEMI patients.

Inclusion Criteria:

• ST elevation myocardial infarction
• Coronary angiography and percutaneous coronary intervention within 12 hours of symptom onset
• Capable and willing to provide informed conset and capable of completing study visits

Exclusion Criteria:

• Cardiovascular shock at admission
• Severe physical disability
• Active malignant tumors
• Active autoimmune diseases